{
    "id": 28914,
    "fullName": "RPS6KA5 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "RPS6KA5 over exp indicates an over expression of the Rps6ka5 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 9252,
        "geneSymbol": "RPS6KA5",
        "terms": [
            "RPS6KA5",
            "MSK1",
            "MSPK1",
            "RLPK"
        ]
    },
    "variant": "over exp",
    "createDate": "11/19/2018",
    "updateDate": "11/19/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15222,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells overexpressing Rps6ka5 (MSK1) were resistant to the PI3K/mTOR inhibitor, DS-7423, as indicated by increased cell viability (PMID: 27196759).",
            "molecularProfile": {
                "id": 30835,
                "profileName": "RPS6KA5 over exp"
            },
            "therapy": {
                "id": 722,
                "therapyName": "DS-7423",
                "synonyms": null
            },
            "indication": {
                "id": 3073,
                "name": "brain glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6791,
                    "pubMedId": 27196759,
                    "title": "MSK1-Mediated \u03b2-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196759"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15221,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cells overexpressing Rps6ka5 (MSK1) were resistant to the PI3K/mTOR inhibitor, Dactolisib (BEZ235), as indicated by increased cell viability (PMID: 27196759).",
            "molecularProfile": {
                "id": 30835,
                "profileName": "RPS6KA5 over exp"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 3073,
                "name": "brain glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6791,
                    "pubMedId": 27196759,
                    "title": "MSK1-Mediated \u03b2-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196759"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30835,
            "profileName": "RPS6KA5 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}